Collagen matrix flap covalently bound to fibroblast growth factor and preparation method thereof

By covalently combining collagen with oxidized sodium alginate and polyamide-amine dendrimers, a collagen matrix flap was prepared, which solved the problems of low growth factor loading rate and insufficient material stability in the treatment of gingival recession, and achieved long-term sustained release of growth factors and cell proliferation promotion effects.

CN119034008BActive Publication Date: 2025-10-03ZHEJIANG UNIV
2 Cites 0 Cited by

Patent Information

Application Number
CN202411166772.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2025-10-03
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

Existing treatments for gum recession have problems such as difficulty in obtaining autologous grafts, high risk of complications, expensive materials and low growth factor loading rate. Existing soft tissue replacement materials have defects in volume stability and degradation rate.

Method used

By cross-linking collagen with oxidized sodium alginate, combining 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide, basic fibroblast growth factor was covalently loaded using polyamidoamine dendrimers to construct a collagen matrix flap to achieve a sustained release effect.

Benefits of technology

It improves the growth factor grafting efficiency, achieves a sustained release effect of up to 28 days, enhances the mechanical properties of the scaffold and promotes cell proliferation activity, and reduces the cytotoxicity risk of the material.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention discloses a collagen matrix flap covalently bound to fibroblast growth factor and a preparation method thereof. The collagen matrix flap is prepared by cross-linking oxidized sodium alginate (OSA) and bovine type I collagen. Subsequently, polyamide-amine dendrimer (PAMAM) is used as a connection carrier to covalently graft basic fibroblast growth factor (bFGF), thereby constructing a scaffold system capable of long-term sustained release of growth factors. The scaffold has good biocompatibility. Experiments have shown that the scaffold of the present invention exhibits clinical operability, superior biological activity to other growth factor-loaded scaffolds, and a more sustained growth factor release effect.
Need to check novelty before this filing date? Find Prior Art